ClinicalTrials.gg
RecruitingNCT06397365HypnOSAUpdated Apr 4, 2025

Effect of Hypnosis on Adherence to Continuous Positive Airway Pressure.

An interventional study of medical hypnosis in Apnea Syndrome and Apnea, Obstructive, sponsored by Solelhac Geoffroy. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Solelhac Geoffroy · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Sleep Apnea Syndromes with a site in Switzerland — 7 open to participants now, 9 under way, none of them phase 3. Sleep Apnea Syndromes · Switzerland.

Planned enrollment
18th of 27
40 · median 60
Started
2025
with 1 other
No phase
21 of 37
5 open now
Registered
32nd of 37
by date

Among the 37 studies in Sleep Apnea Syndromes with a site in Switzerland, this one is the 18th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2025, is one of 21 with no phase, and was the 32nd registered.

Sleep Apnea Syndromes

1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.

Browse Sleep Apnea Syndromes studies →

Open to participants now

7 of the 37 studies in Sleep Apnea Syndromes with a site in Switzerland are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 119 Sleep Apnea Syndromes studies recruiting now, 58 (49%) set no upper age limit and 37 (31%) stop at 75 or younger; 25 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Sleep Apnea Syndromes with a site in Switzerland, or all of them as a file.
02

Study summary

The prevalence of sleep-disordered breathing is high, with an apnea-hypopnea index of over 15 per hour found in 49.7% of men and 23.4% of women in the general population (1). The gold standard treatment for sleep-disordered breathing is continuous positive airway pressure (CPAP) therapy (2). However, nearly 30% of patients are considered non-adherent to CPAP treatment (3). Moreover, the number of hours of CPAP usage has been shown to be directly associated with a reduction in objective and subjective sleepiness, and improvement in daytime functioning (4). A recent prospective study conducted in a French clinical population cohort of 5138 participants found an effect of CPAP treatment duration on reducing the risk of developing a major cardiovascular event (stroke, myocardial infarction, all-cause mortality) (5). Therefore, the poor adherence to CPAP treatment represents a public health challenge for healthcare professionals managing these patients. Several predictors for non-adherence can be identified, such as using CPAP for less than 4 hours per night during the initial treatment phase, moderate to severe obstructive sleep apnea, or low self-esteem (6). Measures aimed at promoting patient adaptation from the initiation of treatment are crucial as this period determines long-term adherence to CPAP therapy (7). Among these measures, there is the management of "physical" adverse effects such as xerostomia (using a humidifier), feeling too much or too little air (modifying CPAP pressure profiles), skin problems, and mask air leaks (interface adjustment), which are well-known and applied by health care organization providing the CPAP machines (2).

On top of these "technical" problems, patients related issues such as mask-induced anxiety, psychosocial conditions, and dysfunctional thoughts about CPAP treatment may prevent patients from using their CPAP properly. Innovative tools such as psycho corporal therapies, including medical hypnosis, could be used in these situations. A recent literature review focusing on the impact of medical hypnosis on sleep disorders in adult patients found an improvement in various sleep parameters (sleep quality, insomnia complaints, frequency and/or intensity of parasomnias) in 58.4% of patients. However, in this systematic review of 24 studies, none of them explored the use of medical hypnosis in sleep-related breathing disorders (8).

Hypnosis can be defined as an altered state of consciousness in which a person's attention is detached from their immediate environment and absorbed in inner experiences such as feelings, cognition, and imagery (9). Hypnotic induction involves focusing attention and imaginative involvement to the point where what is imagined seems real. By using and accepting suggestions, the clinician and the patient create a benevolent hypnotic reality with the goal of improving the patient's clinical situation (10).

In the literature, there is only one clinical case report describing a benefit of medical hypnosis for CPAP tolerance in a child with cherubism (a rare fibro-osseous genetic disease-causing nasal obstruction). In this case, CPAP therapy using an oral interface was fully accepted after three hypnosis sessions and corrected the obstructive sleep breathing disorder (11). In a slightly different domain, there is a case report of successful use of medical hypnosis as an adjunct therapy for weaning from mechanical ventilation (12).

Our hypothesis is that the use of medical hypnosis in CPAP-treated patients could improve the patient's perception of the treatment, making it more positive. Medical hypnosis could occur very early in the management process, with rapid learning of self-hypnosis to actively influence this crucial period for long term adherence of CPAP. The principal objective is therefore to evaluate the effects of medical hypnosis on adherence to CPAP therapy in patients with sleep-disordered breathing.

03

Conditions studied

  • Apnea Syndrome
  • Apnea, Obstructive

Keywords

  • CPAP adherence
  • medical hypnosis
  • obstructive sleep apnea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age
  • Indication for long-term CPAP treatment for sleep-disordered breathing.
  • Intolerance of CPAP with use of less than 3h/night on average (assessed at the second CPAP check-up by the home care provider 1 to 3 months CPAP introduction).
  • Ability to provide .

Exclusion criteria

Exclusion Criteria:

  • Patient's refusal to experience hypnosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Hypnosis

    Baseline study visit (V1): signature of the informed consent form, verification of eligibility criteria, collection of demographic data, polygraphy or polysomnography features, data provided by the CPAP machine (one month), questionnaires. During the second visit (V2), the patient randomized in HYP group will come for the hypnosis sessions. Follow-up visit (V4): 28-42 days (4-6 weeks) after V3 for HYP group and 2 months (+/- 14 days) after V1 for SOC group. Collection of data provided by the CPAP machine (one month), questionnaires.

    Other: medical hypnosis

  • No intervention
    standard of care

    Baseline study visit (V1): signature of the informed consent form, verification of eligibility criteria, collection of demographic data, polygraphy or polysomnography features, data provided by the CPAP machine (one month), questionnaires. Usual management of CPAP treatment by the home care provider and the prescribing doctor without any change in management. Follow-up visit (V4): 28-42 days (4-6 weeks) after V3 for HYP group and 2 months (+/- 14 days) after V1 for SOC group. Collection of data provided by the CPAP machine (one month), questionnaires.

Interventions

  • Othermedical hypnosis

    The first hypnosis session (V2) consists of a safe place suggestion. Through this type of suggestions, patients will safely experience the dissociative state, and will be given tools (recordings of sessions) to perform self-hypnosis at home between the visits. The suggestions will help the patient to visualize an imaginary place where they feel well and safe, a protective place to rest. In this first session, CPAP treatment will be introduced during hypnosis, with specific suggestions relating to the use of this treatment. The second session (V3) The second session will also use the safe place. We will adapt the suggestions according to the experience reported by the patient on the day of the visit. During this session, we'll focus on changes in the patient's perception of the CPAP machine. Patients will also be given the recording of each session to perform self-hypnosis at home between the visits.

06

What researchers measure

Primary outcomes

  1. average hours of CPAP

    average hours of CPAP use before and after the hypnosis therapy.

    Time frame: Baseline after randomisation and at last visit 6 weeks after randomisation

Secondary outcomes

  1. nights with CPAP use of more than 4 hours

    percentage of nights with CPAP use of more than 4 hours before and after the hypnosis therapy

    Time frame: Baseline after randomisation and at last visit 6 weeks after randomisation

  2. patients continuing to use CPAP

    percentage of patients continuing to use CPAP at the end of the study.

    Time frame: Baseline after randomisation and at last visit 6 weeks after randomisation

  3. sleepiness

    Epworth Sleepiness Scale to evaluate daytime sleepiness. (0 to 24. The higher the score, the higher that person's average sleep propensity in daily life or their daytime sleepiness)

    Time frame: Baseline after randomisation and at last visit 6 weeks after randomisation

  4. sleep quality

    Pittsburgh Sleep Quality Index to evaluate sleep quality over a 1-month period. (0 to 21 points, where 0 means that there are no difficulties, and 21 indicating major difficulties.)

    Time frame: Baseline after randomisation and at last visit 6 weeks after randomisation

  5. Insomnia

    Evaluation of the diagnosis of chronic insomnia according to the Insomnia Severity Index.(0 to 28 : Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe))

    Time frame: Baseline after randomisation and at last visit 6 weeks after randomisation

  6. Score at the Quebec Sleep Questionnaire

    Quebec Sleep Questionnaire to evaluate the quality of life related specifically to obstructive sleep apnea. The questionnaire assesses five domains: (1) hypersomnolence; (2) diurnal symptoms; (3) nocturnal symptoms; (4) emotions; and (5) social interactions. Each domain includes 4-7 items and each item is scored on a 7-point scale. For each domain, higher scores indicates milder symptoms.

    Time frame: Baseline after randomisation and at last visit 6 weeks after randomisation

  7. Anxiety and emotion

    The Hospital Anxiety and Depression Scale to evaluate the psychological state. The scale is an instrument for screening for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety and seven others to the depressive dimension. two scores (maximum score for each = 21). A total subscale score of \>8 points out of a possible 21 denotes considerable symptoms of anxiety or depression.

    Time frame: Baseline after randomisation and at last visit 6 weeks after randomisation

07

Study locations

1 of 1 sites recruiting
  • CHUVaudois
    Lausanne, Vaud 1011, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.

Of 202 non-industry interventional studies with no phase under Sleep Apnea Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 60. This study's planned 22 months is below that.

Counting every sponsor, half of 271 studies reached it within 26 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
May 2, 2024
StartActual
Apr 2, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Nov 2027
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06397365
Lead sponsor
Solelhac Geoffroy
Responsible party
Solelhac Geoffroy (MD, Centre Hospitalier Universitaire Vaudois) — Sponsor-investigator
First posted
May 2, 2024
Start date
Apr 2, 2025
Primary completion
Feb 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Apr 4, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion